The trademark application RNA PRINTER was filed by CureVac RNA Printer GmbH, a corporation established under the laws of the Federal Republic of Germany (the "Applicant"). Application refused.
The application was filed in English (German was selected as the second language).
A transfer of the trademark registration was recorded on March 6, 2022.
The Refusal with reference B 018525470 was Rejected according to Article 7(1)(b) EUTMR with decision issued on November 24, 2022 by the EUIPO.
Goods And Services
The mark was filed in class 1 with Chemicals and biomolecules, in particular biological macromolecules, for industrial or scientific purposes and Reagents for research purposes..
The mark was filed in class 5 with following description of goods:
Chemical preparations for medical use
Pharmaceutical and veterinary preparations
Pharmaceuticals and medicines based on biological macromolecules for the treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, for treatment of infectious diseases, allergies, autoimmune disorders and tumour diseases, for treatment of metabolic disorders and for treatment of inherited genetic diseases or for protein or enzyme replacement therapy
Gene therapeutic preparations
Health care preparations for medical use
Dietetic substances adapted for medical use, in particular substances for food supplements.
The mark was filed in class 9 with following description of goods:
Apparatus for chemical synthesis
Mobile laboratory
Mobile device for the synthesis of macromolcules.
The mark was filed in class 42 with Scientific and technological services and research, in particular for identification, testing and characterisation of biological molecules and pre-clinical and clinical testing of macromolecules..
The mark was filed in class 44 with Medical and veterinary services, in particular for therapeutic and preventative treatment of tumour diseases, infectious diseases, autoimmune disorders and allergies, for treatment of inherited genetic diseases or for protein or enzyme replacement therapy, and for treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, and for treatment of metabolic disorders.